(VBK) VERBIO Vereinigte BioEnergie - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A0JL9W6
Biodiesel, Bioethanol, Biomethane, Pharmaceuticals, Fertilizers
VBK EPS (Earnings per Share)
VBK Revenue
Description: VBK VERBIO Vereinigte BioEnergie October 22, 2025
Verbio SE (XETRA:VBK) is a German-based producer of renewable fuels and bio-based chemicals, operating across Biodiesel, Bioethanol/Biomethane, and ancillary “Other” segments. Its product portfolio spans biodiesel, bioethanol, biomethane, pharma-grade glycerine, olefin metathesis catalysts, animal feeds (Verbio Proti Flow, Verbio Grain Pro), phytosterols (Sterocellent), and fertilizers, plus associated trading, transport, and logistics services. Customers range from oil refineries and pharma firms to energy utilities, fleet operators, and agricultural enterprises.
Key quantitative points (as of FY 2023) include: • Annual production capacity of roughly 1.5 Mt of biodiesel and 0.9 Mt of bioethanol, with a 12 % EBITDA margin and net-debt/EBITDA of 2.1×. • Revenue growth of 8 % YoY, driven largely by the EU’s Renewable Energy Directive (RED II) which mandates a 14 % renewable fuel blend in transport fuels by 2025, tightening demand for Verbio’s offerings. • Feedstock cost volatility-particularly the price of rapeseed oil and wheat-remains the primary earnings driver, while the company’s recent acquisition of a U.S. corn-based ethanol plant diversifies its feedstock mix and geographic exposure.
For a deeper quantitative assessment, the ValueRay platform provides a granular view of Verbio’s financials and market positioning.
VBK Stock Overview
| Market Cap in USD | 1,128m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
VBK Stock Ratings
| Growth Rating | -30.2% |
| Fundamental | 15.0% |
| Dividend Rating | 49.2% |
| Return 12m vs S&P 500 | 6.83% |
| Analyst Rating | - |
VBK Dividends
| Dividend Yield 12m | 1.22% |
| Yield on Cost 5y | 0.91% |
| Annual Growth 5y | 18.92% |
| Payout Consistency | 97.5% |
| Payout Ratio | 64.5% |
VBK Growth Ratios
| Growth Correlation 3m | 93.2% |
| Growth Correlation 12m | 37.3% |
| Growth Correlation 5y | -73.4% |
| CAGR 5y | -39.42% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.44 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.59 |
| Sharpe Ratio 12m | -0.31 |
| Alpha | 6.63 |
| Beta | 1.080 |
| Volatility | 53.66% |
| Current Volume | 150.8k |
| Average Volume 20d | 171.4k |
| Stop Loss | 15.4 (-6.2%) |
| Signal | 0.16 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-138.0m TTM) > 0 and > 6% of Revenue (6% = 94.8m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA -5.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.71% (prev 22.20%; Δ -6.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 13.9m > Net Income -138.0m (YES >=105%, WARN >=100%) |
| Net Debt (204.5m) to EBITDA (15.4m) ratio: 13.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.7m) change vs 12m ago -0.66% (target <= -2.0% for YES) |
| Gross Margin 6.49% (prev 17.61%; Δ -11.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 117.9% (prev 120.5%; Δ -2.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.60 (EBITDA TTM 15.4m / Interest Expense TTM 17.7m) >= 6 (WARN >= 3) |
Altman Z'' 1.63
| (A) 0.19 = (Total Current Assets 556.6m - Total Current Liabilities 308.4m) / Total Assets 1.30b |
| (B) 0.15 = Retained Earnings (Balance) 197.7m / Total Assets 1.30b |
| (C) -0.09 = EBIT TTM -117.0m / Avg Total Assets 1.34b |
| (D) 0.45 = Book Value of Equity 238.8m / Total Liabilities 527.6m |
| Total Rating: 1.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 15.02
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -10.02% = -5.0 |
| 3. FCF Margin -7.51% = -2.82 |
| 4. Debt/Equity 0.36 = 2.44 |
| 5. Debt/Ebitda 13.28 = -2.50 |
| 6. ROIC - WACC (= -18.89)% = -12.50 |
| 7. RoE -16.23% = -2.50 |
| 8. Rev. Trend -71.25% = -5.34 |
| 9. EPS Trend -85.08% = -4.25 |
What is the price of VBK shares?
As of November 08, 2025, the stock is trading at EUR 16.42 with a total of 150,819 shares traded.
Over the past week, the price has changed by +6.76%, over one month by +37.29%, over three months by +64.53% and over the past year by +21.82%.
Over the past week, the price has changed by +6.76%, over one month by +37.29%, over three months by +64.53% and over the past year by +21.82%.
Is VERBIO Vereinigte BioEnergie a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, VERBIO Vereinigte BioEnergie (XETRA:VBK) is currently (November 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 15.02 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VBK is around 13.48 EUR . This means that VBK is currently overvalued and has a potential downside of -17.9%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VBK is around 13.48 EUR . This means that VBK is currently overvalued and has a potential downside of -17.9%.
Is VBK a buy, sell or hold?
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
What are the forecasts/targets for the VBK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.3 | -19.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 15.1 | -8.3% |
VBK Fundamental Data Overview January 01, 1970
Market Cap USD = 1.13b (979.9m EUR * 1.1507 EUR.USD)
Market Cap EUR = 979.9m (979.9m EUR * 1.0 EUR.EUR)
P/S = 0.6173
P/B = 1.0015
Beta = 1.08
Revenue TTM = 1.58b EUR
EBIT TTM = -117.0m EUR
EBITDA TTM = 15.4m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 74.2m EUR (from shortTermDebt, last quarter)
Debt = 268.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 204.5m EUR (from netDebt column, last quarter)
Enterprise Value = 1.18b EUR (979.9m + Debt 268.9m - CCE 64.4m)
Interest Coverage Ratio = -6.60 (Ebit TTM -117.0m / Interest Expense TTM 17.7m)
FCF Yield = -10.02% (FCF TTM -118.7m / Enterprise Value 1.18b)
FCF Margin = -7.51% (FCF TTM -118.7m / Revenue TTM 1.58b)
Net Margin = -8.74% (Net Income TTM -138.0m / Revenue TTM 1.58b)
Gross Margin = 6.49% ((Revenue TTM 1.58b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = -16.38% (prev 13.73%)
Tobins Q-Ratio = 0.91 (Enterprise Value 1.18b / Total Assets 1.30b)
Interest Expense / Debt = 3.93% (Interest Expense 10.6m / Debt 268.9m)
Taxrate = 6.37% (-6.63m / -104.1m)
NOPAT = -109.6m (EBIT -117.0m * (1 - 6.37%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 556.6m / Total Current Liabilities 308.4m)
Debt / Equity = 0.36 (Debt 268.9m / totalStockholderEquity, last quarter 746.3m)
Debt / EBITDA = 13.28 (Net Debt 204.5m / EBITDA 15.4m)
Debt / FCF = -1.72 (negative FCF - burning cash) (Net Debt 204.5m / FCF TTM -118.7m)
Total Stockholder Equity = 850.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.60% (Net Income -138.0m / Total Assets 1.30b)
RoE = -16.23% (Net Income TTM -138.0m / Total Stockholder Equity 850.4m)
RoCE = -11.43% (EBIT -117.0m / Capital Employed (Equity 850.4m + L.T.Debt 173.4m))
RoIC = -10.26% (negative operating profit) (NOPAT -109.6m / Invested Capital 1.07b)
WACC = 8.63% (E(979.9m)/V(1.25b) * Re(9.99%) + D(268.9m)/V(1.25b) * Rd(3.93%) * (1-Tc(0.06)))
Discount Rate = 9.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -10.98%
Fair Price DCF = unknown (Cash Flow -118.7m)
EPS Correlation: -85.08 | EPS CAGR: -81.18% | SUE: -2.27 | # QB: 0
Revenue Correlation: -71.25 | Revenue CAGR: -10.73% | SUE: -0.28 | # QB: 0
Market Cap EUR = 979.9m (979.9m EUR * 1.0 EUR.EUR)
P/S = 0.6173
P/B = 1.0015
Beta = 1.08
Revenue TTM = 1.58b EUR
EBIT TTM = -117.0m EUR
EBITDA TTM = 15.4m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 74.2m EUR (from shortTermDebt, last quarter)
Debt = 268.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 204.5m EUR (from netDebt column, last quarter)
Enterprise Value = 1.18b EUR (979.9m + Debt 268.9m - CCE 64.4m)
Interest Coverage Ratio = -6.60 (Ebit TTM -117.0m / Interest Expense TTM 17.7m)
FCF Yield = -10.02% (FCF TTM -118.7m / Enterprise Value 1.18b)
FCF Margin = -7.51% (FCF TTM -118.7m / Revenue TTM 1.58b)
Net Margin = -8.74% (Net Income TTM -138.0m / Revenue TTM 1.58b)
Gross Margin = 6.49% ((Revenue TTM 1.58b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = -16.38% (prev 13.73%)
Tobins Q-Ratio = 0.91 (Enterprise Value 1.18b / Total Assets 1.30b)
Interest Expense / Debt = 3.93% (Interest Expense 10.6m / Debt 268.9m)
Taxrate = 6.37% (-6.63m / -104.1m)
NOPAT = -109.6m (EBIT -117.0m * (1 - 6.37%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 556.6m / Total Current Liabilities 308.4m)
Debt / Equity = 0.36 (Debt 268.9m / totalStockholderEquity, last quarter 746.3m)
Debt / EBITDA = 13.28 (Net Debt 204.5m / EBITDA 15.4m)
Debt / FCF = -1.72 (negative FCF - burning cash) (Net Debt 204.5m / FCF TTM -118.7m)
Total Stockholder Equity = 850.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.60% (Net Income -138.0m / Total Assets 1.30b)
RoE = -16.23% (Net Income TTM -138.0m / Total Stockholder Equity 850.4m)
RoCE = -11.43% (EBIT -117.0m / Capital Employed (Equity 850.4m + L.T.Debt 173.4m))
RoIC = -10.26% (negative operating profit) (NOPAT -109.6m / Invested Capital 1.07b)
WACC = 8.63% (E(979.9m)/V(1.25b) * Re(9.99%) + D(268.9m)/V(1.25b) * Rd(3.93%) * (1-Tc(0.06)))
Discount Rate = 9.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -10.98%
Fair Price DCF = unknown (Cash Flow -118.7m)
EPS Correlation: -85.08 | EPS CAGR: -81.18% | SUE: -2.27 | # QB: 0
Revenue Correlation: -71.25 | Revenue CAGR: -10.73% | SUE: -0.28 | # QB: 0